Novo Nordisk has intensified its campaign against unapproved versions of its blockbuster weight-loss treatment, filing 14 additional lawsuits in U.S. federal courts against compounding pharmacies and telehealth companies it says are steering patients toward knockoff products that claim to contain semaglutide. The Danish drugmaker alleges the firms violate state laws barring the corporate practice of medicine and mislead patients into believing the compounded drugs match the safety and efficacy of FDA-cleared medicines such as Wegovy and Ozempic. With the new filings, Novo Nordisk has initiated 132 complaints in 40 states and has already obtained 44 permanent injunctions blocking the sale or marketing of what it describes as unsafe or mislabeled semaglutide products. The latest suits come days after the U.S. Food and Drug Administration warned clinicians and consumers about overdoses and other risks tied to compounded GLP-1 drugs that use ingredients the agency says often originate from unregulated suppliers in China. Separately, the company faces fresh legal pressure from shareholders, who sued in U.S. court claiming Novo Nordisk overstated future demand for its obesity therapies and downplayed competitive threats, allegedly inflating the share price. Novo Nordisk said it will address the investor allegations while continuing efforts to curb illicit versions of its medicines.